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Abstract
Background: There is no functional pharmacovigilance system in Cambodia to our knowledge. Mobile phone–based tools,
such as short message service (SMS) text messages, are increasingly used for surveillance purposes.
Objective: To pilot-test the FrontlineSMS mobile phone–based tool for notification of adverse events, using Cambodia’s only
International Vaccination Center at the Institut Pasteur du Cambodge as a field site.
Methods: People receiving vaccinations, aged over 18 years, and who owned a cell phone were recruited in the study following
informed consent. The names and mobile phone numbers of the participants interviewed were entered each day into the
FrontlineSMS software. Two days after being vaccinated, participants received an automatically generated SMS text message
asking whether any adverse events had occurred. Their SMS reply was number-coded and exported from the software daily to
an Excel spreadsheet and examined before being saved. If the participant replied with a code for a severe adverse event (8 or 9),
they were automatically advised to consult the nearest doctor.
Results: The active surveillance study was conducted over 72 days in the spring of 2012. Patients agreed to be asked by SMS
text message whether unwanted events had occurred after vaccination. Of 1331 persons aged over 18 years referred to the
vaccination unit, 184 (13.8%) were asked and agreed to participate. When texted for clinical status 48 hours after vaccination,
52 (28.3%) participants did not reply, 101 (54.9%) sent an immediate SMS reply, and 31 (16.8%) sent an SMS reply after additional
prompting. Of the initial 184 participants, 132 (71.7%) replied. These 132 participants received 135 vaccine doses and 109 (82.6%)
reported no adverse events, whereas 23 (17.4%) reported adverse events, all benign.
Conclusions: Notification using an SMS-based text message system is already used in Cambodia for syndromic surveillance
in health centers and reporting by health care workers. Our results show that such tools can also be useful for notification by
patients or health users in Cambodia, especially in an urban setting.
(J Med Internet Res 2013;15(4):e68)   doi:10.2196/jmir.2477
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Introduction
The burden of disease can be threefold in developing countries
faced with communicable diseases, noncommunicable diseases,
and sociobehavioral illnesses [1]. Most of these may require
treatment or prevention through medication or vaccines. In
addition to the expectable adverse events in the normal usage
of registered drugs, developing countries also face a plague of
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counterfeit or substandard drugs [2-5]. Pharmacovigilance—a
form of epidemiological surveillance that monitors the
occurrence of adverse events of drugs [6,7] or vaccines [8-10]
to guide timely corrective action and mitigate risk—is an
essential tool for patient safety in developed countries and in
an increasing number of developing countries [11]. Cambodia,
a developing country in Southeast Asia, is not among the 109
countries participating in the World Health Organization (WHO)
Programme for International Drug Monitoring maintained in
collaboration with the Uppsala Monitoring Center in Uppsala,
Sweden [12]. To our knowledge, there is no functional
pharmacovigilance program in Cambodia.
Pharmacovigilance has been conducted using complex and
rigorous notification procedures in developed countries, but it
faces challenges in developing countries because of issues with
clinician awareness, clinical expertise, or nonfunctional
reporting systems [11,13,14]. Therefore, some programs or
countries have circumvented these challenges by implementing
mobile phone-based and Web-based tools using short message
service (SMS) text messaging for immediate notification of
adverse events [15,16].
FrontlineSMS is one such reporting tool [17]. It has been used
in Cambodia for various health-related projects, but always for
information exchange among health providers and stakeholders
[18-20]. An Epidemiology Master student helped pilot its use
for surveillance in direct link with health users in a vaccination
center. More than 25,000 vaccine doses were administered to
16,630 health users in 2012 (Figure 1) referred to the
International Vaccination Center at the Institut Pasteur du
Cambodge (IPC), the only such vaccination center in Cambodia
(Figure 2). The aim of this study was to field-test the
FrontlineSMS software to see whether it could provide effective
and timely notification of vaccine adverse events.
Figure 1. Vaccination at the International Vaccination Center, Institut Pasteur du Cambodge.
J Med Internet Res 2013 | vol. 15 | iss. 4 | e68 | p.2http://www.jmir.org/2013/4/e68/
(page number not for citation purposes)
Baron et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
Figure 2. The waiting room of the international vaccination center at the Institut Pasteur du Cambodge.
Method
The research project received ethical approval from the national
ethics committee on health research on February 17, 2012. Data
collection began March 12, 2012, and ended May 31, 2012.
During that period, a research assistant from the epidemiology
and public health unit at IPC (a native Khmer speaker) spent
several hours each day at the International Vaccination Center
to recruit participants. Participants were eligible to be included
in the study if they were aged over 18 years, came to the center
to be vaccinated themselves (ie, not for their children), agreed
to participate, owned a cell phone, and knew how to send SMS
text messages. If so, the research assistant informed them about
the study, read through the protocol, explained the objectives
of the pharmacovigilance project in Khmer, and asked the
participants to complete an informed consent form. Information
about their name, age, place of residence, type of vaccine, and
mobile phone service provider were collected. The names and
mobile phone numbers of the participants interviewed were
entered each day in the FrontlineSMS software.
Two days after being vaccinated, participants received an
automatically generated SMS text message. This message
thanked them for participating and asked whether any adverse
events had occurred. Their SMS reply was number-coded as
follows: 0=no adverse event, 1=mainly redness and/or pain at
the injection site, 2=mainly fatigue and/or weakness, 3=mainly
headaches, 4=mainly fever, 5=mainly runny or congested nose,
6=mainly muscle pains, 7=mainly abdominal pain, 8=seizures
or neurological problems, and 9=severe allergic reaction. Only
1 code was allowed per reply. Messages received were exported
from the software daily to an Excel spreadsheet and examined
before being saved.
Upon receiving the text reply, a software-generated message
was sent. If the codes corresponded to no or a moderate adverse
event (codes 0-7), the reply was: “We have received your
message. Thank you for having participated.” If the participant
sent back a code for a severe adverse event (8 or 9), the reply
read: “You have reported a severe adverse event. Please consult
the nearest doctor as soon as possible. If in Phnom Penh, we
recommend that you refer to Hôpital Calmette.” (The Hôpital
Calmette is a national reference hospital where the emergency
department team had been informed of the study.) In cases when
a severe adverse event was reported, the research assistant called
the participant’s cell phone number directly to follow-up on the
participant. If the case was referred to Hôpital Calmette,
transportation costs were covered by the study. There was no
other financial compensation to participants, including for costs
associated with sending SMS text messages.
Results
The study took place between March 13 and May 25, 2012, for
a total of 72 days: 53 days of which the International
Vaccination Center was open and 19 days of which it was closed
(weekend or national holidays, Figure 3). During some of those
days, the research assistant did not recruit participants because
she was involved in another study.
During the 53 days that the International Vaccination Center
was open in that period, 1331 persons aged over 18 years (684
women and 647 men) came for vaccinations at the center (mean
25.1 persons aged ≥18 years per day, Figure 4).
Of the 1331 vaccinees, 184 were asked and agreed to participate
to this pilot study (97 female, 87 male). Of these 184
participants, 165 (90.2%) resided in Phnom Penh; 6 (3.3%) in
Kampong Speu; 3 (1.6%) each in Kandal and Kompong Cham,
respectively; 2 (1.1%) in Siem Reap; and 1 (0.5%) each in
Takeo, Battambang, Mondulkiri, and Rattanakiri, respectively.
Mean age of all 1331 health users during that period was 34.8
years (SD 12.7, range 18-95), although the subgroup of study
participants was younger (mean 26.9 years, SD 7.8, range
18-65). The 184 participants subscribed to 6 cell phone
companies, the largest of which accounted for 83 (45.1%) of
the participants.
The 184 health users who initially agreed to participate in the
study received a total of 192 vaccine doses for 17 different
diseases (Table 1).
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Table 1. Vaccines administered to study participants and reported adverse events for the pharmacovigilance pilot study at the Institut Pasteur du
Cambodge from March to May 2012 (N=184).
TotalNo reply
Mainly runny
or congested
noseMainly fever
Mainly fatigue
and/or weakness
Mainly redness
and/or pain at
the injection
site
No adverse
eventVaccinea
1000001Hepatitis A
7730013439Hepatitis B
3001002Haemophilus influenza
10100009Japanese encephalitis
1100000MMR
2000002Meningitis
1000001Chickenpox
4200002Pneumococcus
1100000Rubella
203001313Tetanus
4200002Tetanus & rabies
5010112DTCP
2000002Typhoid
204210310HPV
225000017Influenza
2000002Influenza & Hib
1000001Influenza & tetanus
1000010Rabies
6200004Yellow fever
1100000Yellow fever & meningitis
1845233512109Total
a MMR: measles, mumps, rubella; DTCP: diphtheria, tetanus, pertussis, polio; HPV: human papillomavirus; Hib: Haemophilus influenzae serotype B.
Most of the vaccinations given were against hepatitis B (41.8%),
influenza (11.9%), tetanus (10.9%), and human papillomavirus
(HPV) (10.9%). Fifty-two participants (28.2%) did not send a
reply (including 30 of 77 who received vaccination against
hepatitis B), and 132 (71.7%) did send a reply, of which 101
(76.5%) completed the study as per the study protocol and sent
a correct SMS text reply, whereas 31 (23.5%) participants had
to be contacted twice because they replied incorrectly or did
not reply at all (Figure 2). These 132 respondents received a
total of 137 doses of vaccine. In all, 109 (82.6%) respondents
reported no occurrences of adverse events, whereas 23 (17.4%)
did report adverse events, none of which were severe (Table 1).
Twelve (52.2%) of these adverse events pertained to redness at
the injection site, and 3 (13.0%) pertained to fever. The time
between the initial sending of the SMS text and the reply from
participants was documented in 120 messages (mean 0.4 days,
SD 0.82, range 0-5). The reply was received within the same
day in 91 (75.8%) of documented answers.
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Figure 3. Number of health users at the international vaccination center and inclusions in the SMS pilot study, Institut Pasteur du Cambodge, March-May
2012.
Figure 4. Flowchart of patient recruitment in the pilot SMS text-based pharmacovigilance study at International Vaccination Center, Institut Pasteur
du Cambodge, March-May 2012 (percentage total may not equal 100% due to rounding).
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Discussion
The objective of this pilot study was to assess the feasibility of
an SMS text-based reporting tool for pharmacovigilance in
Cambodia. According to the International Communications
Union database, there were 69.9 mobile-cellular telephone
subscriptions per 100 (%) inhabitants in Cambodia in 2011
(slightly less than India), up from 7.95% in 2005 [21]. This
translates to approximately 10 million cellular telephone
subscriptions in Cambodia in 2011, a country with an estimated
population of approximately 14 million [22].
To our knowledge, this pilot SMS text-based system for active
detection of adverse events following vaccination is the first
functional pharmacovigilance system in Cambodia, the first
SMS text-based surveillance system relying on health users’
participation in Cambodia, and the first to use SMS text-based
surveillance for adverse event detection anywhere [20]. In this
project, operating costs were modest, with only part-time activity
dedicated to entering cell phone numbers, downloading SMS
replies, and checking that no SMS texts received alerted to
severe adverse events.
During the 2.5-month pilot phase, the participation rate was
high with a 71.7% response rate. Of 77 persons who were
vaccinated against hepatitis B, 30 (39%) sent no reply. Although
this percentage may seem high, the hepatitis B vaccines were
the most frequently administered, and the small study group
makes nonreply percentages vary greatly.
With 132 participants replying and 24 reporting adverse events
(none severe), the prevalence of adverse events was slightly
higher than expected. The expected rate of adverse events
following immunization is estimated to be in the order of 10%,
except for diphtheria, tetanus, pertussis (DTP) or tetanus
boosters in which fever occurs in nearly half of recipients [23].
In 2008, in Australia, 1542 adverse events (7.2 per 100,000
population) following immunization were notified by
manufacturers, health professionals, or the public [24]. This
passive surveillance system also includes children, who are the
main recipients of vaccines. Of these adverse events, 41% were
site reactions and 16% were fevers. Our data, albeit on a far
more modest scale and not including children, showed
comparable percentages (52.2% and 13.0%, respectively). A
study conducted in the United Kingdom showed that patients
tend to report more benign adverse drug reactions than health
care providers, and concluded that patient-based
pharmacovigilance may usefully complement health care
provider reporting of adverse events [25].
The participants’ response rate was unexpectedly high, probably
enhanced by the use of short and simple SMS text-based reply
codes. This research project also had a research assistant to
explain the protocol at length in the national language, which
would not be the case in a daily operational setting where a
simple leaflet or poster would provide information to the health
users.
Our study suffers from biases and limitations. Firstly, the
number of participants was very limited. The epidemiological
findings of such a small and short study on adverse events are
difficult to extrapolate. Secondly, the patients recruited all
attended the IPC’s International Vaccination Center in Phnom
Penh. Costs there may be higher because of state-of-the-art
quality control carried out on vaccines imported primarily from
Europe. Therefore, recruitment may have been biased toward
younger, more affluent, well-informed, urban residents more
accustomed to sending SMS text messages. This limits the
possibility of extending similar systems outside of large urban
centers within Cambodia, at least in the short term. Experience
with SMS text-based surveillance in the rural setting found that
many farmers did not know how to send text messages [18].
Thirdly, only the last-generation cellular telephones support
Khmer fonts or pictures of Khmer-language text, whereas the
vast majority of cellular phones do not. Lastly, some operators
mainly offer voice-based communications and no data or SMS
text transfers because telephone communications are relatively
cheap and there is no advantage to sending a text message.
Bearing these limitations in mind, this small pilot study serves
as a proof of concept that health user–sent, SMS text-based
surveillance strategies can be used in an urban Cambodian
setting. This is an important step in Cambodia where health
surveillance systems facing numerous challenges may often be
dysfunctional and where pharmacovigilance is absent. Our
secondary objective was also met, which was to become
proficient in the use of FrontlineSMS for other potential
applications. Technology for mobile telephone–based active
surveillance appears to be cheap, easy to implement, simple,
and quick to be mastered by field staff. This approach will be
used by the Epidemiology and Public Health Unit at the Institut
Pasteur du Cambodge to implement follow-up programs, such
as monitoring outcomes in rabies postexposure prophylaxis at
IPC’s Rabies Prevention Clinic (over 20,300 referrals in 2011)
or in prospective studies on dengue in urban settings.
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